Otsuka Plans $2.8 Billion IPO To Feed Global Expansion
This article was originally published in The Pink Sheet Daily
Still fueled by growth of the anti-psychotic Abilify, the Japanese pharma's parent company plans to list on the Tokyo Stock Exchange on December 15.
You may also be interested in...
Otsuka Holdings, the parent company of Japan's fifth-largest pharmaceutical company Otsuka Pharmaceutical, could go public on the Tokyo Stock Exchange within the year
New claim puts the atypical antipsychotic on par with J&J's Risperdal.
The related deals between Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. announced in April appear to be a win for both sides. They extend and update a highly successful 10-year-old collaboration, essentially tweaking the original agreement's terms in consideration of each partner's current needs. At the same time, they recognize that the key product involved, the antipsychotic medication Abilify, is reaching maturity.